MMED (Minimed Group) 3-Year RORE % : 0.00% (As of Jan. 2026)


MMED Minimed Group Inc MMED
15 GF Score
Price $14.28
! 1 Warning Sign
View Full Analysis

What is Minimed Group 3-Year RORE %?

Minimed Group MMED +0.14% 15 3-Year RORE % is 0.00 as of Jan. 2026. GuruFocus rates MMED with a GF Score™ of 15/100. The stock has 1 warning sign investors should review. Among 782 Medical Devices & Instruments companies, Minimed Group ranks worse than 127877.11% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Minimed Group does not have enough data to calculate 3-Year RORE %.


Minimed Group  (NAS:MMED) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Minimed Group 3-Year RORE % Related Terms


Minimed Group 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Minimed Group's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Minimed Group 3-Year RORE % Chart

Minimed Group Annual Data
Trend Apr23 Apr24 Apr25
3-Year RORE %
0.00 0.00 0.00

Minimed Group Quarterly Data
Apr24 Jan25 Apr25 Oct25 Jan26
3-Year RORE % 0.00 0.00 0.00 0.00 0.00

MMED vs ICUI, WRBY, MMSI: 3-Year RORE % Comparison

For the Medical Instruments & Supplies subindustry, Minimed Group's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Minimed Group 3-Year RORE % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Minimed Group's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Minimed Group's 3-Year RORE % falls into.


MMED
15GF Score
Minimed Group Inc MMED
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Minimed Group 3-Year RORE % Calculation

Minimed Group's 3-Year RORE % for the quarter that ended in Jan. 2026 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( - )/( - )
=/
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jan. 2026 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of 0.00 mean?
Minimed Group (MMED) has a 3-Year RORE % of 0.00 as of Jan. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Minimed Group and its competitors. According to the industry distribution chart, Minimed Group ranks #999999 out of 782 companies in the Medical Devices & Instruments industry.
Is Minimed Group's 3-Year RORE % too high?
Minimed Group's current 3-Year RORE % is 0.00. Based on the distribution chart, Minimed Group ranks #999999 out of 782 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Minimed Group has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Minimed Group's 3-Year RORE % compare to ICUI and WRBY?
According to the Medical Devices & Instruments industry distribution chart, Minimed Group ranks #999999 out of 782 companies for 3-Year RORE %. This places Minimed Group in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Devices & Instruments company?
A good 3-Year RORE % depends on the Medical Devices & Instruments industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Minimed Group and its competitors. Minimed Group's current 3-Year RORE % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minimed Group stock overvalued right now?
Minimed Group (MMED) has a current 3-Year RORE % of 0.00. The current 3-Year RORE % is 0.00. Minimed Group's overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Minimed Group (MMED), the current 3-Year RORE % is 0.00 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Minimed Group Business Description

Other Exchanges B8S:Germany
Address 18000 Devonshire Street, Northridge, CA, USA, 91325
Minimed Group Inc is a medical technology firm that develops, manufactures, and markets products and solutions for diabetes management. It offers automated insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens as its main products. The company sells these through direct-to-consumer channels and healthcare providers of various countries. The company's revenues are principally derived from the sale of reusable and single-use products which together comprise AID systems and smart multiple daily injection (MDI) systems for diabetes management to individuals, distributors, healthcare providers, and other institutions globally.
15GF Score

Get the complete analysis for MMED

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.28
Price